Trevi Therapeutics Inc (Nasdaq: TRVI), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Margaret Garin, MD, MSCR, as its new vice president of Clinical Development.
In the new role, Dr Garin will be responsible for advancing the clinical development of the company's Haduvio in chronic cough.
Dr Garin has more than 14 years of industry and academic research experience and more than nine years of global pharmaceutical industry experience in early and late-stage development. She has served as the executive director of Clinical Development at Bellus Health (now owned by GSK). She was the clinical development lead for programs in respiratory and inflammation at Teva Pharmaceuticals.
Regeneron and Sanofi's Dupixent gains EU approval for uncontrolled COPD with eosinophilia
INOVIO names new chief commercial officer
Carisma Therapeutics names new directors
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
Biophytis signs Latin American deal with Blanver for BIO101 (20-Hydroxyecdysone)
Natera unveils enhanced Prospera Heart test for transplant patients
Biophytis reports industrial scale production of DMD drug candidate BIO101
EMA grants orphan drug designation to Moleculin's Annamycin for AML
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
ProAxsis secures GBP1.8m investment
CareDx highlights cardiothoracic advancements at ISHLT meeting